---
title: Tumor burden quantified by Soluble B-Cell Maturation Antigen and Metabolic
  Tumor Volume determine myeloma CAR-T outcomes
date: '2024-12-09'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39652773/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20241209184147&v=2.18.0.post9+e462414
source: Blood
description: Chimeric antigen receptor T-cell (CAR-T) therapy has emerged as a breakthrough
  treatment for relapsed and refractory multiple myeloma (RRMM). However, these products
  are complex to deliver and alternative options are now available. Identifying biomarkers
  that can predict therapeutic outcomes is crucial for optimizing patient selection.
  There is a paucity of data evaluating the utility of both serum soluble B-cell maturation
  antigen (sBCMA) levels and metabolic tumor volume (MTV) at baseline ...
disable_comments: true
---
Chimeric antigen receptor T-cell (CAR-T) therapy has emerged as a breakthrough treatment for relapsed and refractory multiple myeloma (RRMM). However, these products are complex to deliver and alternative options are now available. Identifying biomarkers that can predict therapeutic outcomes is crucial for optimizing patient selection. There is a paucity of data evaluating the utility of both serum soluble B-cell maturation antigen (sBCMA) levels and metabolic tumor volume (MTV) at baseline ...